Navigation Links
Uroplasty Reports Fiscal Second Quarter 2012 Financial Results
Date:10/27/2011

MINNEAPOLIS, Oct. 27, 2011 /PRNewswire/ -- Uroplasty, Inc. (Nasdaq: UPI), a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, today reported financial results for the second quarter of fiscal 2012 ended September 30, 2011.

Global sales increased 53% to $5.0 million in the fiscal second quarter of 2012, compared with $3.2 million in the fiscal second quarter last year.  The growth reflects continued strong sales in the U.S., up 86% in the fiscal second quarter compared with the prior year.  U.S. sales growth was driven by a 95% increase in sales of the Urgent PC Neuromodulation System and a 75% increase in sales of Macroplastique.

"This was a strong quarter for Uroplasty, reflecting growth in both Urgent PC Systems and Macroplastique products, demonstrating solid execution of our plans to drive sales," said David Kaysen, President and CEO of Uroplasty, Inc.  "The number of active U.S. Urgent PC customers during the fiscal second quarter increased over the fiscal first quarter by 108 to a record of 509.  We sold 2,579 lead set boxes in the U.S. during the quarter, an increase of 30% over the fiscal first quarter of 1,985. The strength in Macroplastique sales was the result of our focus on this product line to quickly capture share with the exit of a former competitor from the market."  

Urgent PC sales in the U.S. were $2.0 million in the quarter ended September 30, 2011, compared with $1.0 million in the same quarter last year.  The growth in Urgent PC sales is the result of the expanded sales and marketing efforts the Company has made subsequent to obtaining the new Category I CPT® code for posterior tibial nerve stimulation (PTNS) that became effective in January 2011, and the increased reimbursement coverage by insurance carriers. Reimbursement coverag
'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Uroplasty to Issue Second Quarter 2012 Financial Results on October 27, 2011
2. Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference
3. Uroplasty Reports Financial Results for the First Quarter of Fiscal 2012
4. Uroplasty to Issue First Quarter 2012 Financial Results on July 28, 2011
5. Two Additional Private Payers Provide Coverage for Posterior Tibial Nerve Stimulation Delivered Using the Uroplasty Urgent® PC Neuromodulation System
6. Uroplasty on Preliminary List of Additions to Russell 3000® and Russell Global® Indexes
7. Uroplastys Dave Kaysen to Ring NASDAQ Closing Bell
8. Uroplasty Reports Financial Results for the Fiscal Fourth Quarter and Full Year 2011
9. Uroplasty to Present at the JMP Securities Research Conference
10. Clinical Studies Results of Uroplasty Products Scheduled for Presentation at Three Professional Meetings
11. Uroplasty Announces Expanded Insurance Coverage of Posterior Tibial Nerve Stimulation (PTNS) Delivered Using the Urgent® PC Neuromodulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Calif. , Sept. 2, 2015  ArmaGen, ... developing revolutionary therapies to treat severe neurological disorders, ... dosed in its multi-center Phase 1/2a clinical trial ... I (MPS I). AGT-181 is ... treatment of MPS I. The most severe form ...
(Date:9/2/2015)... , Sept. 2, 2015  Boca Raton ... FACS, has begun performing ultra-minimally invasive left atrial ... on anticoagulants such as Coumadin, Xarelto or Effient. ... at the Hospital, is one of a select ... involves making two microscopic incisions in order to ...
(Date:9/2/2015)... Elekta, a global cancer management company, ... 10, 6:30-8:30 p.m., at Elekta,s North American headquarters in ... " will feature Professional BMX athlete, Josh Perry , ... with Leksell Gamma Knife®, Elekta,s radiosurgery system for treating brain ... be diagnosed in Georgia in 2015 ...
Breaking Medicine Technology:ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 2ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 3ArmaGen Announces First Patient Dosed in Phase 1/2a Clinical Trial of AGT-181 for the Treatment of Hurler Syndrome 4Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 2Elekta to Host Cancer Survivorship Event at Company's Learning and Innovation Center (LINC) in Atlanta 3
... , SEATTLE , Sept. 21 ... that it will re-focus its resources on the approval of OPAXIO(TM) ... The Gynecologic Oncology Group (GOG) is conducting an ongoing phase III ... versus an untreated control arm. To date, 600 patients have been ...
... , , THOUSAND ... ) today announced detailed results from a Phase 3 trial ... an intravenous infusion in the treatment of bone metastases in ... and prostate cancer) or multiple myeloma. These results were ...
Cached Medicine Technology:Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis 2Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis 3Pivotal Registration Trial of OPAXIO Maintenance Therapy in First-Line Ovarian Cancer Reaches Enrollment Milestone of 600 patients, Cell Therapeutics and the Gynecologic Oncology Group Discuss Potential for Early Interim Analysis 4Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 2Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 3Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 4Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 5Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 6Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 7Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 8Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases 9
(Date:9/2/2015)... ... ... article published August 12 by International Business Times, a new bill was signed ... in cases meant to decide if a police officer used deadly or excessive force in ... and New York City that absolved police officers of charges in the deaths of two ...
(Date:9/2/2015)... ... September 02, 2015 , ... Specifically, ... the news recently following a decision by the Centers for Medicare & Medicaid ... to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price tag. ...
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an ... of its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone ... usability. A leader in health technology, RxNT was one of the first to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... intermediate or final products. Automating sample handling makes density measurements more efficient and ... each step of the automated workflow and the advantages compared to manual sample ...
(Date:9/2/2015)... ... 2015 , ... A UPMC and University of Pittsburgh Schools ... a premier center for treatment of and research into hereditary hemorrhagic telangiectasia (HHT), ... , Cure HHT, previously known as The HHT Foundation International, has designated ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4
... BEIJING, June 26 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin ... China, Beijing RainEarth Technology Co. Ltd., ("China RainEarth"),has obtained ... that aid in manufacturing blood dialysis. , ... for patents for its core,technology with the State Intellectual ...
... HOUSTON, June 26 The Breast Center at Houston Northwest ... the United States -- and one in Texas -- to ... by the National Quality Measures for Breast Centers (NQMBC) Program(TM). ... measure performance of interdisciplinary breast care nationwide. The designation is ...
... ... in Omaha list for the second straight year. The list is sponsored by the Greater Omaha ... an Omaha business. , ... June 26, 2009 -- Healthcare staffing company Medical Solutions has landed on the ...
... DC (26 June, 2009) Combating high blood pressure ... enjoyed reductions in cardiovascular disease over recent decades, Latin ... published in the journal Therapeutic Advances in Cardiovascular ... the increase in many Latin American countries, a situation ...
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ... the Food and Drug Administration, today arrived and seized ... also included ingredients held at these same facilities. The ... in May 2009, found unresolved violations of cGMP requirements ...
... Texas, June 25 Torchmark Corporation (NYSE: TMK ... $300 million in aggregate principal amount of 9.25% Senior Notes ... to close on June 30, 2009, subject to the satisfaction ... offering will be used for the repayment of the $99.45 ...
Cached Medicine News:Health News:RainEarth Obtains Patent Approvals for Its Core Technology 2Health News:RainEarth Obtains Patent Approvals for Its Core Technology 3Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 2Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 2Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 4Health News:Latin America must cut blood pressure to thrive 2Health News:Latin America must cut blood pressure to thrive 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action 2Health News:Torchmark Prices Senior Notes Offering 2
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
Medicine Products: